BioSpace News Archive

The COVID-19 Immunity Task Force and the Vaccine Surveillance Reference Group are announcing a new study led by Sunnybrook researchers, which seeks to better understand the effectiveness of COVID-19 vaccination in patients with chronic kidney disease.

Biodesix, Inc. announced Scott Hutton, Chief Executive Officer of Biodesix, will present in a fireside chat the Morgan Stanley Virtual 19th Annual Global Healthcare Conference being held virtually September 9-10 and September 13-15, 2021.

Alligator Bioscience AB announces that the Company, in order to enable further progress, will begin evaluating potential financing alternatives, which may include issuance of equity.

Tetra Bio-Pharma Inc., a leader in cannabinoid-derived drug discovery and development is pleased to announce that it received the Scientific Advice Assessment Report from the Malta Medicines Authority.

Passage Bio, Inc. announced that Bruce Goldsmith, Ph.D., president and chief executive officer of Passage Bio, will participate in a virtual panel presentation, titled “What’s Next for Neurodegenerative Diseases,” at the upcoming Citi 16th Annual BioPharma Virtual Conference, September 8-10, 2021.

Ikena Oncology, Inc., a targeted oncology company focused on developing novel cancer therapies targeting key signaling pathways, announced that management will participate in the virtual Morgan Stanley 19th Annual Global Healthcare Conference taking place on September 9-15, 2021, and the H.C. Wainwright 23rd Annual Global Investment Conference, taking place on September 13-15, 2021.

Calithera Biosciences, Inc., a fully-integrated clinical stage biotechnology company focused on discovering and developing novel, small molecule drugs for the treatment of cancer and other life-threatening diseases, announced its participation in two upcoming virtual healthcare investor conferences.

Instil Bio, Inc., a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, announced that company management will participate in two upcoming investor conferences in September:

Plus Therapeutics, Inc., a U.S. clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, announced that it has entered into an agreement with RadioMedix, Inc. for the commercial production of the Company’s radiopharmaceuticals.

Amydis Inc., a leading ocular tracer pharmaceutical company with a broad portfolio of diagnostic drug candidates targeting CNS biomarkers in the eye, announced a new Phase 1 grant award from the National Institute of Aging at the National Institutes of Health.